Skip to main content
Erschienen in: Brain Tumor Pathology 1/2021

08.09.2020 | Original Article

Frequency of mismatch repair protein deficiency and PD-L1 in high-grade gliomas in adolescents and young adults (AYA)

verfasst von: Ghadeer Almuhaisen, Yazan Alhalaseh, Razan Mansour, Amer Abu-Shanab, Sura Al-Ghnimat, Maysa Al-Hussaini

Erschienen in: Brain Tumor Pathology | Ausgabe 1/2021

Einloggen, um Zugang zu erhalten

Abstract

Central nervous system tumors in adolescents and young adults (AYA) are rarely reported in the literature. The association with cancer predisposition syndrome is not established. Programmed death ligand 1 (PD-L1) can predict the potential response of patients to immunotherapy. A link between mismatch repair protein deficiency (MMRP-D) and response to immunotherapy is established. P53 is reported to be positive in MMRD-D cases. We aim to investigate the frequency of MMRP-D in AYA with high-grade glioma and any potential association with PD-L1. A total of 96 cases were tested including 49 (51.0%) cases of glioblastoma. Six cases (6.25%) were MMRP-D, 17 (17.7%) were PD-L1 positive, mostly in grade IV tumors (8.7% in grade III compared to 26% in grade IV, p value = 0.027), and 69 (71.9%) were P3 positive. None of the MMRP-D cases expressed PD-L1. P53-positive cases were mostly MMRP proficient (n = 67; 74.4%, p value 0.051). Fourteen cases (28.7%) were positive for both PD-L1 and P53, while p53-positive grade IV tumors were mostly associated with negative PD-L1 (n = 29, 58%, p value = 0.043). MMRP deficiency does not appear to be prevalent in high-grade glioma in AYA. Expression of PD-L1 in a quarter of cases might suggest a role for immunotherapy in high-grade glioma.
Literatur
1.
Zurück zum Zitat Ostrom QT, Gittleman H, de Blank PM, Finlay JL, Gurney JG, McKean-Cowdin R, Stearns DS, Wolff JE, Liu M, Wolinsky Y, Kruchko C, Barnholtz-Sloan JS (2016) American brain tumor association adolescent and young adult primary brain and central nervous system tumors diagnosed in the United States in 2008–2012. Neuro Oncol 18(Suppl 1):i1–i50CrossRef Ostrom QT, Gittleman H, de Blank PM, Finlay JL, Gurney JG, McKean-Cowdin R, Stearns DS, Wolff JE, Liu M, Wolinsky Y, Kruchko C, Barnholtz-Sloan JS (2016) American brain tumor association adolescent and young adult primary brain and central nervous system tumors diagnosed in the United States in 2008–2012. Neuro Oncol 18(Suppl 1):i1–i50CrossRef
2.
Zurück zum Zitat Bleyer A, Barr R, Hayes-Lattin B, Thomas D, Ellis C, Anderson B, Biology and Clinical Trials Subgroups of the US National Cancer Institute Progress Review Group in Adolescent and Young Adult Oncology (2008) The distinctive biology of cancer in adolescents and young adults. Nat Rev Cancer 8(4):288–298CrossRef Bleyer A, Barr R, Hayes-Lattin B, Thomas D, Ellis C, Anderson B, Biology and Clinical Trials Subgroups of the US National Cancer Institute Progress Review Group in Adolescent and Young Adult Oncology (2008) The distinctive biology of cancer in adolescents and young adults. Nat Rev Cancer 8(4):288–298CrossRef
3.
Zurück zum Zitat Zapotocky M, Ramaswamy V (2018) Adolescents and young adults with brain tumors in the context of molecular advances in neuro-oncology. Pediatr Blood Cancer 65(2):e26861CrossRef Zapotocky M, Ramaswamy V (2018) Adolescents and young adults with brain tumors in the context of molecular advances in neuro-oncology. Pediatr Blood Cancer 65(2):e26861CrossRef
4.
Zurück zum Zitat Bleyer A, Budd T, Montello M (2006) Adolescents and young adults with cancer: the scope of the problem and criticality of clinical trials. Cancer 107(7 Suppl):1645–1655CrossRef Bleyer A, Budd T, Montello M (2006) Adolescents and young adults with cancer: the scope of the problem and criticality of clinical trials. Cancer 107(7 Suppl):1645–1655CrossRef
5.
Zurück zum Zitat Georgakis MK, Panagopoulou P, Papathoma P, Tragiannidis A, Ryzhov A, Zivkovic-Perisic S, Eser S, Taraszkiewicz L, Sekerija M, Zagar T, Antunes L, Zborovskaya A, Bastos J, Florea M, Coza D, Demetriou A, Agius D, Strahinja RM, Sfakianos G, Nikas I, Kosmidis S, Razis E, Pourtsidis A, Kantzanou M, Dessypris N, Petridou ET (2017) Central nervous system tumours among adolescents and young adults (15–39 years) in Southern and Eastern Europe: registration improvements reveal higher incidence rates compared to the US. Eur J Cancer 86:46–58CrossRef Georgakis MK, Panagopoulou P, Papathoma P, Tragiannidis A, Ryzhov A, Zivkovic-Perisic S, Eser S, Taraszkiewicz L, Sekerija M, Zagar T, Antunes L, Zborovskaya A, Bastos J, Florea M, Coza D, Demetriou A, Agius D, Strahinja RM, Sfakianos G, Nikas I, Kosmidis S, Razis E, Pourtsidis A, Kantzanou M, Dessypris N, Petridou ET (2017) Central nervous system tumours among adolescents and young adults (15–39 years) in Southern and Eastern Europe: registration improvements reveal higher incidence rates compared to the US. Eur J Cancer 86:46–58CrossRef
6.
Zurück zum Zitat Xie C, Sheng H, Zhang N, Li S, Wei X, Zheng X (2016) Association of MSH6 mutation with glioma susceptibility, drug resistance and progression. Mol Clin Oncol 5(2):236–240CrossRef Xie C, Sheng H, Zhang N, Li S, Wei X, Zheng X (2016) Association of MSH6 mutation with glioma susceptibility, drug resistance and progression. Mol Clin Oncol 5(2):236–240CrossRef
7.
Zurück zum Zitat Stark AM, Doukas A, Hugo HH, Mehdorn HM (2010) The expression of mismatch repair proteins MLH1, MSH2 and MSH6 correlates with the Ki67 proliferation index and survival in patients with recurrent glioblastoma. Neurol Res 32(8):816–820CrossRef Stark AM, Doukas A, Hugo HH, Mehdorn HM (2010) The expression of mismatch repair proteins MLH1, MSH2 and MSH6 correlates with the Ki67 proliferation index and survival in patients with recurrent glioblastoma. Neurol Res 32(8):816–820CrossRef
8.
Zurück zum Zitat Li GM (2008) Mechanisms and functions of DNA mismatch repair. Cell Res 18(1):85–98CrossRef Li GM (2008) Mechanisms and functions of DNA mismatch repair. Cell Res 18(1):85–98CrossRef
9.
Zurück zum Zitat Leung SY, Chan TL, Chung LP, Chan AS, Fan YW, Hung KN, Kwong WK, Ho JW, Yuen ST (1998) Microsatellite instability and mutation of DNA mismatch repair genes in gliomas. Am J Pathol 153(4):1181–1188CrossRef Leung SY, Chan TL, Chung LP, Chan AS, Fan YW, Hung KN, Kwong WK, Ho JW, Yuen ST (1998) Microsatellite instability and mutation of DNA mismatch repair genes in gliomas. Am J Pathol 153(4):1181–1188CrossRef
10.
Zurück zum Zitat Daniel P, Sabri S, Chaddad A, Meehan B, Jean-Claude B, Rak J, Abdulkarim BS (2019) Temozolomide induced hypermutation in glioma: evolutionary mechanisms and therapeutic opportunities. Front Oncol 9:41CrossRef Daniel P, Sabri S, Chaddad A, Meehan B, Jean-Claude B, Rak J, Abdulkarim BS (2019) Temozolomide induced hypermutation in glioma: evolutionary mechanisms and therapeutic opportunities. Front Oncol 9:41CrossRef
11.
Zurück zum Zitat Lang FF, Miller DC, Koslow M, Newcomb EW (1994) Pathways leading to glioblastoma multiforme: a molecular analysis of genetic alterations in 65 astrocytic tumors. J Neurosurg 81(3):427–436CrossRef Lang FF, Miller DC, Koslow M, Newcomb EW (1994) Pathways leading to glioblastoma multiforme: a molecular analysis of genetic alterations in 65 astrocytic tumors. J Neurosurg 81(3):427–436CrossRef
12.
Zurück zum Zitat Leung SY, Yuen ST, Chan TL, Chan AS, Ho JW, Kwan K, Fan YW, Hung KN, Chung LP, Wyllie AH (2000) Chromosomal instability and p53 inactivation are required for genesis of glioblastoma but not for colorectal cancer in patients with germline mismatch repair gene mutation. Oncogene 19(35):4079–4083CrossRef Leung SY, Yuen ST, Chan TL, Chan AS, Ho JW, Kwan K, Fan YW, Hung KN, Chung LP, Wyllie AH (2000) Chromosomal instability and p53 inactivation are required for genesis of glioblastoma but not for colorectal cancer in patients with germline mismatch repair gene mutation. Oncogene 19(35):4079–4083CrossRef
13.
Zurück zum Zitat Amayiri N, Tabori U, Campbell B, Bakry D, Aronson M, Durno C, Rakopoulos P, Malkin D, Qaddoumi I, Musharbash A, Swaidan M, Bouffet E, Hawkins C, Al-Hussaini M (2016) High frequency of mismatch repair deficiency among pediatric high grade gliomas in Jordan. Int J Cancer 138(2):380–385CrossRef Amayiri N, Tabori U, Campbell B, Bakry D, Aronson M, Durno C, Rakopoulos P, Malkin D, Qaddoumi I, Musharbash A, Swaidan M, Bouffet E, Hawkins C, Al-Hussaini M (2016) High frequency of mismatch repair deficiency among pediatric high grade gliomas in Jordan. Int J Cancer 138(2):380–385CrossRef
14.
Zurück zum Zitat Le DT, Uram JN, Wang H, Bartlett BR, Kemberling H, Eyring AD, Skora AD, Luber BS, Azad NS, Laheru D, Biedrzycki B, Donehower RC, Zaheer A, Fisher GA, Crocenzi TS, Lee JJ, Duffy SM, Goldberg RM, de la Chapelle A, Koshiji M, Bhaijee F, Huebner T, Hruban RH, Wood LD, Cuka N, Pardoll DM, Papadopoulos N, Kinzler KW, Zhou S, Cornish TC, Taube JM, Anders RA, Eshleman JR, Vogelstein B, Diaz LA Jr (2015) PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med 372(26):2509–2520CrossRef Le DT, Uram JN, Wang H, Bartlett BR, Kemberling H, Eyring AD, Skora AD, Luber BS, Azad NS, Laheru D, Biedrzycki B, Donehower RC, Zaheer A, Fisher GA, Crocenzi TS, Lee JJ, Duffy SM, Goldberg RM, de la Chapelle A, Koshiji M, Bhaijee F, Huebner T, Hruban RH, Wood LD, Cuka N, Pardoll DM, Papadopoulos N, Kinzler KW, Zhou S, Cornish TC, Taube JM, Anders RA, Eshleman JR, Vogelstein B, Diaz LA Jr (2015) PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med 372(26):2509–2520CrossRef
15.
Zurück zum Zitat Garber ST, Hashimoto Y, Weathers SP, Xiu J, Gatalica Z, Verhaak RG, Zhou S, Fuller GN, Khasraw M, de Groot J, Reddy SK, Spetzler D, Heimberger AB (2016) Immune checkpoint blockade as a potential therapeutic target: surveying CNS malignancies. Neuro Oncol 18(10):1357–1366CrossRef Garber ST, Hashimoto Y, Weathers SP, Xiu J, Gatalica Z, Verhaak RG, Zhou S, Fuller GN, Khasraw M, de Groot J, Reddy SK, Spetzler D, Heimberger AB (2016) Immune checkpoint blockade as a potential therapeutic target: surveying CNS malignancies. Neuro Oncol 18(10):1357–1366CrossRef
16.
Zurück zum Zitat Hodges TR, Ott M, Xiu J, Gatalica Z, Swensen J, Zhou S, Huse JT, de Groot J, Li S, Overwijk WW, Spetzler D, Heimberger AB (2017) Mutational burden, immune checkpoint expression, and mismatch repair in glioma: implications for immune checkpoint immunotherapy. Neuro Oncol 19(8):1047–1057CrossRef Hodges TR, Ott M, Xiu J, Gatalica Z, Swensen J, Zhou S, Huse JT, de Groot J, Li S, Overwijk WW, Spetzler D, Heimberger AB (2017) Mutational burden, immune checkpoint expression, and mismatch repair in glioma: implications for immune checkpoint immunotherapy. Neuro Oncol 19(8):1047–1057CrossRef
17.
Zurück zum Zitat Lee V, Murphy A, Le DT, Diaz LA Jr (2016) Mismatch repair deficiency and response to immune checkpoint blockade. Oncologist 21(10):1200–1211CrossRef Lee V, Murphy A, Le DT, Diaz LA Jr (2016) Mismatch repair deficiency and response to immune checkpoint blockade. Oncologist 21(10):1200–1211CrossRef
18.
Zurück zum Zitat Joyce JA (2005) Therapeutic targeting of the tumor microenvironment. Cancer Cell 7(6):513–520CrossRef Joyce JA (2005) Therapeutic targeting of the tumor microenvironment. Cancer Cell 7(6):513–520CrossRef
19.
Zurück zum Zitat Schiffer D, Annovazzi L, Casalone C, Corona C (2018) Glioblastoma: microenvironment and niche concept. Cancers 11(1):5CrossRef Schiffer D, Annovazzi L, Casalone C, Corona C (2018) Glioblastoma: microenvironment and niche concept. Cancers 11(1):5CrossRef
20.
Zurück zum Zitat Bazzoni R, Bentivegna A (2019) Role of notch signaling pathway in glioblastoma pathogenesis. Cancers 11(3):292CrossRef Bazzoni R, Bentivegna A (2019) Role of notch signaling pathway in glioblastoma pathogenesis. Cancers 11(3):292CrossRef
21.
Zurück zum Zitat Hovinga KE, Shimizu F, Wang R, Panagiotakos G, Van Der Heijden M, Moayedpardazi H, Correia AS, Soulet D, Major T, Menon J, Tabar V (2010) Inhibition of notch signaling in glioblastoma targets cancer stem cells via an endothelial cell intermediate. Stem Cells 28(6):1019–1029CrossRef Hovinga KE, Shimizu F, Wang R, Panagiotakos G, Van Der Heijden M, Moayedpardazi H, Correia AS, Soulet D, Major T, Menon J, Tabar V (2010) Inhibition of notch signaling in glioblastoma targets cancer stem cells via an endothelial cell intermediate. Stem Cells 28(6):1019–1029CrossRef
22.
Zurück zum Zitat Jacquelot N, Roberti MP, Enot DP, Rusakiewicz S, Ternès N, Jegou S, Woods DM, Sodré AL, Hansen M, Meirow Y, Sade-Feldman M, Burra A, Kwek SS, Flament C, Messaoudene M, Duong CPM, Chen L, Kwon BS, Anderson AC, Kuchroo VK, Weide B, Aubin F, Borg C, Dalle S, Beatrix O, Ayyoub M, Balme B, Tomasic G, Di Giacomo AM, Maio M, Schadendorf D, Melero I, Dréno B, Khammari A, Dummer R, Levesque M, Koguchi Y, Fong L, Lotem M, Baniyash M, Schmidt H, Svane IM, Kroemer G, Marabelle A, Michiels S, Cavalcanti A, Smyth MJ (2017) Predictors of responses to immune checkpoint blockade in advanced melanoma. Nat Commun 8(1):592CrossRef Jacquelot N, Roberti MP, Enot DP, Rusakiewicz S, Ternès N, Jegou S, Woods DM, Sodré AL, Hansen M, Meirow Y, Sade-Feldman M, Burra A, Kwek SS, Flament C, Messaoudene M, Duong CPM, Chen L, Kwon BS, Anderson AC, Kuchroo VK, Weide B, Aubin F, Borg C, Dalle S, Beatrix O, Ayyoub M, Balme B, Tomasic G, Di Giacomo AM, Maio M, Schadendorf D, Melero I, Dréno B, Khammari A, Dummer R, Levesque M, Koguchi Y, Fong L, Lotem M, Baniyash M, Schmidt H, Svane IM, Kroemer G, Marabelle A, Michiels S, Cavalcanti A, Smyth MJ (2017) Predictors of responses to immune checkpoint blockade in advanced melanoma. Nat Commun 8(1):592CrossRef
23.
Zurück zum Zitat Zhu C, Zhuang W, Chen L, Yang W, Ou WB (2020) Frontiers of ctDNA, targeted therapies, and immunotherapy in non-small-cell lung cancer. Transl Lung Cancer Res 9(1):111–138CrossRef Zhu C, Zhuang W, Chen L, Yang W, Ou WB (2020) Frontiers of ctDNA, targeted therapies, and immunotherapy in non-small-cell lung cancer. Transl Lung Cancer Res 9(1):111–138CrossRef
24.
Zurück zum Zitat Li Y, He M, Zhou Y, Yang C, Wei S, Bian X, Christopher O, Xie L (2019) The prognostic and clinicopathological roles of PD-L1 expression in colorectal cancer: a systematic review and meta-analysis. Front Pharmacol 10:139CrossRef Li Y, He M, Zhou Y, Yang C, Wei S, Bian X, Christopher O, Xie L (2019) The prognostic and clinicopathological roles of PD-L1 expression in colorectal cancer: a systematic review and meta-analysis. Front Pharmacol 10:139CrossRef
25.
Zurück zum Zitat Xue S, Song G, Yu J (2017) The prognostic significance of PD-L1 expression in patients with glioma: a meta-analysis. Sci Rep 7(1):4231CrossRef Xue S, Song G, Yu J (2017) The prognostic significance of PD-L1 expression in patients with glioma: a meta-analysis. Sci Rep 7(1):4231CrossRef
26.
Zurück zum Zitat Louis DN, Ohgaki H, Wiestler OD, Cavenee WK (2016) WHO classification of tumours of the central nervous system, 4th edition revised, 4th edn. IARC, Geneva Louis DN, Ohgaki H, Wiestler OD, Cavenee WK (2016) WHO classification of tumours of the central nervous system, 4th edition revised, 4th edn. IARC, Geneva
27.
Zurück zum Zitat O'Regan T, Chau K, Tatton M, Smith T, Parry S, Bissett I (2013) Immunochemistry screening for Lynch syndrome in colorectal adenocarcinoma using an initial two antibody panel can replace a four antibody panel. N Z Med J 126(1382):70–77PubMed O'Regan T, Chau K, Tatton M, Smith T, Parry S, Bissett I (2013) Immunochemistry screening for Lynch syndrome in colorectal adenocarcinoma using an initial two antibody panel can replace a four antibody panel. N Z Med J 126(1382):70–77PubMed
28.
Zurück zum Zitat Zeng J, Zhang XK, Chen HD, Zhong ZH, Wu QL, Lin SX (2016) Expression of programmed cell death-ligand 1 and its correlation with clinical outcomes in gliomas. Oncotarget 7(8):8944–8955CrossRef Zeng J, Zhang XK, Chen HD, Zhong ZH, Wu QL, Lin SX (2016) Expression of programmed cell death-ligand 1 and its correlation with clinical outcomes in gliomas. Oncotarget 7(8):8944–8955CrossRef
29.
Zurück zum Zitat Stark AM, Nabavi A, Mehdorn HM, Blomer U (2005) Glioblastoma multiforme-report of 267 cases treated at a single institution. Surg Neurol 63(2):162–169 CrossRef Stark AM, Nabavi A, Mehdorn HM, Blomer U (2005) Glioblastoma multiforme-report of 267 cases treated at a single institution. Surg Neurol 63(2):162–169 CrossRef
30.
Zurück zum Zitat Diwanji TP, Engelman A, Snider JW, Mohindra P (2017) Epidemiology, diagnosis, and optimal management of glioma in adolescents and young adults. Adolesc Health Med Ther 8:99–113CrossRef Diwanji TP, Engelman A, Snider JW, Mohindra P (2017) Epidemiology, diagnosis, and optimal management of glioma in adolescents and young adults. Adolesc Health Med Ther 8:99–113CrossRef
31.
Zurück zum Zitat Papageorgiou GI, Razis ED (2020) CNS tumors in adolescents and young adults: the need for a holistic specialized approach. JCO Oncol Pract 16(4):155–162CrossRef Papageorgiou GI, Razis ED (2020) CNS tumors in adolescents and young adults: the need for a holistic specialized approach. JCO Oncol Pract 16(4):155–162CrossRef
Metadaten
Titel
Frequency of mismatch repair protein deficiency and PD-L1 in high-grade gliomas in adolescents and young adults (AYA)
verfasst von
Ghadeer Almuhaisen
Yazan Alhalaseh
Razan Mansour
Amer Abu-Shanab
Sura Al-Ghnimat
Maysa Al-Hussaini
Publikationsdatum
08.09.2020
Verlag
Springer Singapore
Erschienen in
Brain Tumor Pathology / Ausgabe 1/2021
Print ISSN: 1433-7398
Elektronische ISSN: 1861-387X
DOI
https://doi.org/10.1007/s10014-020-00379-7

Weitere Artikel der Ausgabe 1/2021

Brain Tumor Pathology 1/2021 Zur Ausgabe

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.